C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more
C4 Therapeutics Inc (CCCC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.086x
Based on the latest financial reports, C4 Therapeutics Inc (CCCC) has a cash flow conversion efficiency ratio of -0.086x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.14 Million) by net assets ($256.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
C4 Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how C4 Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
C4 Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of C4 Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Protara Therapeutics Inc
NASDAQ:TARA
|
-0.094x |
|
Boryung Pharm
KO:003850
|
0.060x |
|
PERMA-PIPE INTL HLDGS
F:MF3
|
N/A |
|
John Mattson Fastighetsforetagen AB
ST:JOMA
|
0.008x |
|
Curacle Co. Ltd.
KQ:365270
|
-0.092x |
|
NEXCOM International Co Ltd
TWO:8234
|
0.017x |
|
I-PEX Inc.
OTCGREY:DAIKF
|
N/A |
|
Solbar Ningbo Protein Technology Co., Ltd.
SHG:603231
|
0.053x |
Annual Cash Flow Conversion Efficiency for C4 Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of C4 Therapeutics Inc from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $256.59 Million | $-98.69 Million | -0.385x | -27.50% |
| 2024-12-31 | $215.99 Million | $-65.16 Million | -0.302x | +30.51% |
| 2023-12-31 | $246.11 Million | $-106.84 Million | -0.434x | -18.52% |
| 2022-12-31 | $289.23 Million | $-105.94 Million | -0.366x | -64.09% |
| 2021-12-31 | $389.61 Million | $-86.97 Million | -0.223x | +6.80% |
| 2020-12-31 | $280.79 Million | $-67.25 Million | -0.239x | +51.78% |
| 2019-12-31 | $-111.96 Million | $55.61 Million | -0.497x | -333.28% |
| 2018-12-31 | $-79.75 Million | $-16.98 Million | 0.213x | -- |